Skip to main
ATAI
ATAI logo

ATAI Stock Forecast & Price Target

ATAI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atai Beckley NV's clinical candidate BPL-003 has shown promising results, exhibiting significantly improved MADRS scores and a doubling of remission rates after the second dose, indicating a potential for enhanced clinical response. With an estimated 20% market share by 2035 due to its clinical differentiation, the company appears well-positioned for growth in the treatment-resistant depression sector. Furthermore, the strong year-to-date stock performance, coupled with anticipated regulatory alignment for Phase 3 trials and upcoming efficacy data, suggests continued optimism regarding its clinical pipeline and market potential.

Bears say

Atai Beckley NV's clinical trials indicate a concerning decline in efficacy of its treatments, with significant deterioration observed in both VLS-01 and BPL-003 from earlier assessment points. The company's Phase 3 results showed a placebo-adjusted change in the MADRS score that lagged behind competitors, such as Spravato, highlighting a potential competitive disadvantage in efficacy metrics. Furthermore, limited safety data from preliminary studies raises questions about the risk profile of the company's dual-dose induction therapy, compounding the uncertainty around its upcoming projects and overall market viability.

ATAI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atai Life Sciences BV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atai Life Sciences BV (ATAI) Forecast

Analysts have given ATAI a Strong Buy based on their latest research and market trends.

According to 4 analysts, ATAI has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atai Life Sciences BV (ATAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.